Aclaris Therapeutics, Inc. (FRA:8AT)
Germany · Delayed Price · Currency is EUR | Market Cap | 782.05M +370.3% |
| Revenue (ttm) | 7.19M -51.0% |
| Net Income | -66.29M |
| EPS | -0.51 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 5.55 |
| Previous Close | 5.37 |
| Day's Range | 5.55 - 5.55 |
| 52-Week Range | 1.50 - 5.55 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Aclaris Therapeutics
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational... [Read more]
Financial Performance
In 2025, Aclaris Therapeutics's revenue was $7.83 million, a decrease of -58.19% compared to the previous year's $18.72 million. Losses were -$64.92 million, -50.84% less than in 2024.
Financial numbers in USD Financial StatementsNews
Aclaris Therapeutics receives FDA Fast Track Designation for Modzatinib
Aclaris Therapeutics (ACRS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation for modzatinib for moderate to severe lichen planus including oral erosive LP, cutan...
Aclaris Therapeutics files automatic mixed securities shelf
17:09 EDT Aclaris Therapeutics (ACRS) files automatic mixed securities shelf
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammato...
Aclaris Therapeutics reports Q2 EPS (15c), consensus (16c)
Reports Q2 revenue $1.6M, consensus $1.38M. As of June 30, Aclaris had cash, cash equivalents and marketable securities of $170.6M vs. $151.4M as of December 31, 2025. The company believes…
Aclaris Therapeutics Earnings release: Q2 2026
Aclaris Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Aclaris Therapeutics Quarterly report: Q2 2026
Aclaris Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Timelines Reaffirmed for Upcoming Top Line Res...
Aclaris Therapeutics management to meet with Oppenheimer
Meeting to be held on June 16 hosted by Oppenheimer.
Aclaris Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Multiple clinical programs are advancing, with key data readouts for bispecific and TSLP mAb assets expected in the second half of the year. The bispecific program is prioritized, with phase II asthma trials starting in Q4, while small molecule and next-gen ITK assets are positioned for future growth.
Aclaris Therapeutics Transcript: AGM 2026
The meeting covered board elections, executive compensation, and auditor ratification, with all proposals approved. A quorum was present, and no stockholder questions were submitted during the Q&A session.
Aclaris Therapeutics initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Aclaris Therapeutics (ACRS) with an Outperform rating and $13 price target
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammator...
Aclaris Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Innovative immunology pipeline targets dermatologic and respiratory diseases with both biologics and small molecules, including best-in-class anti-TSLP and ITK inhibitors. Multiple phase II and IND milestones are expected by year-end, supported by a strong cash position.
Aclaris Therapeutics Slides: FY 2026
Aclaris Therapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 14, 2026.
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammator...
Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)
Reports Q1 revenue $2M, consensus $1.32M. “Since the start of 2026, we have made great progress toward our goal of developing best-in-class compounds to address a variety of immuno-inflammatory diseas...
Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)
Reports Q1 revenue $2M, consensus $1.32M. “Since the start of 2026, we have made great progress toward our goal of developing best-in-class compounds to address a variety of immuno-inflammatory diseas...
Aclaris Therapeutics Earnings release: Q1 2026
Aclaris Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Aclaris Therapeutics Quarterly report: Q1 2026
Aclaris Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Aclaris Therapeutics Slides: Corporate presentation
Aclaris Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Unique Dual ...
Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler
Piper Sandler analyst Biren Amin raised the firm’s price target on Aclaris Therapeutics (ACRS) to $11 from $7 and keeps an Overweight rating on the shares following the company’s update…
Aclaris Therapeutics initiated with a Buy at Guggenheim
Guggenheim last night initiated coverage of Aclaris Therapeutics (ACRS) with a Buy rating and $12 price target The company has a promising interleukin-2-inducible T-cell kinase franchise strategy and ...
Aclaris Therapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Seamus Fernandez initiated coverage of Aclaris Therapeutics (ACRS) with a Buy rating and $12 price target
Aclaris Therapeutics price target raised to $10 from $8 at Wedbush
Wedbush analyst Martin Fan raised the firm’s price target on Aclaris Therapeutics (ACRS) to $10 from $8 and keeps an Outperform rating on the shares. The firm notes the company…